GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Roivant Sciences Ltd (FRA:87S) » Definitions » EV-to-EBIT

Roivant Sciences (FRA:87S) EV-to-EBIT : 0.45 (As of Jun. 25, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Roivant Sciences EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Roivant Sciences's Enterprise Value is €1,752.1 Mil. Roivant Sciences's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was €3,923.5 Mil. Therefore, Roivant Sciences's EV-to-EBIT for today is 0.45.

The historical rank and industry rank for Roivant Sciences's EV-to-EBIT or its related term are showing as below:

FRA:87S' s EV-to-EBIT Range Over the Past 10 Years
Min: -7.75   Med: -3.12   Max: 1.03
Current: 0.44

During the past 4 years, the highest EV-to-EBIT of Roivant Sciences was 1.03. The lowest was -7.75. And the median was -3.12.

FRA:87S's EV-to-EBIT is ranked better than
78.49% of 437 companies
in the Biotechnology industry
Industry Median: 8.79 vs FRA:87S: 0.44

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Roivant Sciences's Enterprise Value for the quarter that ended in Mar. 2024 was €2,309.9 Mil. Roivant Sciences's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was €3,923.5 Mil. Roivant Sciences's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 169.85%.


Roivant Sciences EV-to-EBIT Historical Data

The historical data trend for Roivant Sciences's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Roivant Sciences EV-to-EBIT Chart

Roivant Sciences Annual Data
Trend Mar21 Mar22 Mar23 Mar24
EV-to-EBIT
- -2.25 -4.06 0.69

Roivant Sciences Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.06 -6.18 -7.48 0.78 0.69

Competitive Comparison of Roivant Sciences's EV-to-EBIT

For the Biotechnology subindustry, Roivant Sciences's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Roivant Sciences's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Roivant Sciences's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Roivant Sciences's EV-to-EBIT falls into.



Roivant Sciences EV-to-EBIT Calculation

Roivant Sciences's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=1752.091/3923.468
=0.45

Roivant Sciences's current Enterprise Value is €1,752.1 Mil.
Roivant Sciences's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €3,923.5 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Roivant Sciences  (FRA:87S) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Roivant Sciences's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2024 ) =EBIT / Enterprise Value (Q: Mar. 2024 )
=3923.468/2309.9086
=169.85 %

Roivant Sciences's Enterprise Value for the quarter that ended in Mar. 2024 was €2,309.9 Mil.
Roivant Sciences's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €3,923.5 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Roivant Sciences EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Roivant Sciences's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Roivant Sciences (FRA:87S) Business Description

Traded in Other Exchanges
Address
50 Broadway, 7th Floor, London, GBR, SW1H 0BD
Roivant Sciences Ltd is a biopharmaceutical company dedicated to improving the delivery of healthcare to patients.

Roivant Sciences (FRA:87S) Headlines

No Headlines